Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $36.33

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $36.33.

Several research firms have commented on VRDN. The Goldman Sachs Group upped their price objective on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. BTIG Research upped their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. TD Cowen initiated coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating on the stock. HC Wainwright upped their price objective on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Finally, Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Monday, November 25th.

Viridian Therapeutics Stock Down 5.2 %

Shares of NASDAQ:VRDN opened at $17.99 on Tuesday. The firm has a 50 day simple moving average of $22.16 and a 200-day simple moving average of $17.80. Viridian Therapeutics has a twelve month low of $11.40 and a twelve month high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.43 billion, a PE ratio of -4.17 and a beta of 1.04.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.08 million. On average, equities analysts predict that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, CEO Stephen F. Mahoney purchased 21,400 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $23.33 per share, with a total value of $499,262.00. Following the purchase, the chief executive officer now owns 21,400 shares in the company, valued at approximately $499,262. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Thomas W. Beetham acquired 5,000 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at approximately $140,460. This trade represents a 500.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.65% of the company’s stock.

Institutional Investors Weigh In On Viridian Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC raised its stake in shares of Viridian Therapeutics by 344.0% in the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after acquiring an additional 4,692 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Viridian Therapeutics in the third quarter valued at about $149,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Viridian Therapeutics by 24.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after purchasing an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC boosted its position in shares of Viridian Therapeutics by 108.3% in the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock worth $163,000 after buying an additional 6,500 shares during the period. Finally, Arizona State Retirement System grew its stake in shares of Viridian Therapeutics by 14.7% in the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after buying an additional 1,688 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.